4th European Biotech & MedTech Investor Day

by France Biotech

June 4, 2018
Boston - USA
**MISSION**

Genkyotex is a clinical stage biopharmaceutical company developing breakthrough NOX driven therapies. The Company is currently developing therapies for liver, kidney and lung fibrosis.

**TECHNOLOGY**

Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.

**ALLIANCES/PARTNERSHIPS**

Serum Institute of India Private Limited (SIIL)

**UPCOMING CATALYSTS**

Interim/Final results in a phase 2 clinical trial with GKT831 in PBC

**MARKET FIGURES**

Revenues 2017: na

Date of IPO: 28.02.2017

Ticker: GKTX

Exchange: Euronext Paris and Brussels

Currency: EUR

Market cap: 116 MEUR

Price: 1.5 EUR

52-weeks-high: 2.55 EUR

52-weeks-low: 1.44 EUR

Average daily volume: 94 K in 2018

**ANALYST COVERAGE**

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco. (buy/neutral/hold)</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roth</td>
<td>16.01.2017</td>
<td>Buy</td>
<td>6.00 EUR</td>
<td>+300%</td>
</tr>
<tr>
<td>Oddo</td>
<td>27.10.2017</td>
<td>Buy</td>
<td>2.90 EUR</td>
<td>+93%</td>
</tr>
<tr>
<td>Edisson</td>
<td>2017</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LifeSci</td>
<td>2017</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Average</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**SHAREHOLDERS**

Andera Partners: 23.76%

Eclosion 2 & Cie SCPC: 17.90%

Vesalius Biocapital: 8.88%

Neomed: 7.27%
The fibrosis market spans across multiple indications in organs such as the lung, the liver, the kidney, the eye, and the skin. Fibrosis is also implicated in oncology; it is estimated that about 45% of all deaths in the developed world are related to fibrosis.